脂蛋白(a)与动脉粥样硬化性心血管病及主动脉瓣狭窄:欧洲动脉粥样硬化学会共识声明
2022年欧洲动脉粥样硬化学会Lp(a)共识声明更新了Lp(a)在ASCVD和主动脉瓣狭窄中作用的证据,并为检测和治疗Lp(a)升高提供临床指导。大规模流行病学和遗传学研究支持Lp(a)浓度与心血管结局存在因果和连续关联,建议成人至少检测一次Lp(a),在无特异性降Lp(a)疗法时推荐早期强化危险因素管理。
要点
- Lp(a)是ASCVD的因果危险因素,即使在LDL-C极低水平时仍增加风险。
- 建议成人至少检测一次Lp(a),特定人群可考虑级联检测。
- 无特异性降Lp(a)药物时,应基于整体风险和Lp(a)水平强化危险因素管理。
核心结论
- Lp(a)是心血管结局的因果危险因素,特异性降Lp(a)治疗试验对确认临床获益至关重要。
研究设计与样本
- 欧洲动脉粥样硬化学会专家小组制定的共识声明,基于涉及数十万个体的流行病学和遗传学研究证据。
主要发现
- Lp(a)浓度与不同种族心血管结局呈因果和连续关联,LDL-C极低时Lp(a)升高仍是危险因素。
- 高Lp(a)与主动脉瓣微钙化和宏钙化均相关。
- 现有证据不支持Lp(a)为静脉血栓事件和纤溶受损的危险因素。
- 极低Lp(a)水平可能与糖尿病风险增加相关,值得进一步研究。
- Lp(a)具有促炎和促动脉粥样硬化特性,部分可能与Lp(a)携带的氧化磷脂有关。
关键数值与推荐
- 建议成人至少检测一次Lp(a)浓度。
- 级联检测在家族性高胆固醇血症、家族史或个人史为(极)高Lp(a)或早发ASCVD时可能有价值。
- 无特异性降Lp(a)疗法时,推荐早期强化危险因素管理,根据整体心血管风险和Lp(a)水平靶向治疗。
- 脂蛋白血浆置换是极高水平Lp(a)伴进行性心血管病且危险因素管理已最优化的选择。
临床怎么用
- 成人至少检测一次Lp(a),对早发ASCVD或家族性高胆固醇血症等特定人群考虑级联检测。
- 无特异性降Lp(a)药物时,根据整体心血管风险和Lp(a)水平早期强化危险因素管理。
- 极高水平Lp(a)且进行性心血管病尽管危险因素已最优化管理,可考虑脂蛋白血浆置换。
局限性
- 当前缺乏特异性降Lp(a)疗法,需等待特异性降Lp(a)治疗试验确认临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates evidence for the role of Lp(a) in atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, provides clinical guidance for testing and treating elevated Lp(a) levels, and considers its inclusion in global risk estimation. Epidemiologic and genetic studies involving hundreds of thousands of individuals strongly support a causal and continuous association between Lp(a) concentration and cardiovascular outcomes in different ethnicities; elevated Lp(a) is a risk factor even at very low levels of low-density lipoprotein cholesterol. High Lp(a) is associated with both microcalcification and macrocalcification of the aortic valve. Current findings do not support Lp(a) as a risk factor for venous thrombotic events and impaired fibrinolysis. Very low Lp(a) levels may associate with increased risk of diabetes mellitus meriting further study. Lp(a) has pro-inflammatory and pro-atherosclerotic properties, which may partly relate to the oxidized phospholipids carried by Lp(a). This panel recommends testing Lp(a) concentration at least once in adults; cascade testing has potential value in familial hypercholesterolaemia, or with family or personal history of (very) high Lp(a) or premature ASCVD. Without specific Lp(a)-lowering therapies, early intensive risk factor management is recommended, targeted according to global cardiovascular risk and Lp(a) level. Lipoprotein apheresis is an option for very high Lp(a) with progressive cardiovascular disease despite optimal management of risk factors. In conclusion, this statement reinforces evidence for Lp(a) as a causal risk factor for cardiovascular outcomes. Trials of specific Lp(a)-lowering treatments are critical to confirm clinical benefit for cardiovascular disease and aortic valve stenosis.
引用
- Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022. PMID: 36036785. doi:10.1093/eurheartj/ehac361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。